GENE ONLINE|News &
Opinion
Blog

2025-11-27|

Medication and Cognitive Behavioral Therapy Identified as Most Effective ADHD Treatments in Largest Analysis to Date

by GOAI
Share To

A recent extensive analysis of treatments for Attention Deficit Hyperactivity Disorder (ADHD) has identified medication and cognitive behavioral therapy (CBT) as the most effective options. The review, which is described as the largest of its kind to date, highlights that medication demonstrates strong short-term efficacy for both children and adults with ADHD, while CBT shows significant effectiveness specifically for adults. These findings are supported by robust evidence from clinical trials.

The study examined a wide range of treatment approaches for ADHD, evaluating their effectiveness based on trial data. Researchers concluded that medication consistently provided substantial benefits in managing symptoms across age groups, making it a reliable option for both children and adults. For adult patients, CBT emerged as another leading intervention, offering notable improvements in coping strategies and symptom management. The analysis underscores the importance of these two methods in addressing ADHD symptoms effectively within short-term treatment frameworks.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top